NCT07003100View on ClinicalTrials.gov

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

October 19, 2026

Study Completion Date

October 19, 2026

Conditions
Recurrent Mycosis FungoidesRecurrent Sezary SyndromeRefractory Mycosis FungoidesRefractory Sezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
OTHER

Non-Interventional Study

Non-interventional study

Trial Locations (10)

19107

NOT_YET_RECRUITING

Thomas Jefferson University Hospital, Philadelphia

21287

NOT_YET_RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

30322

NOT_YET_RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

33612

NOT_YET_RECRUITING

Moffitt Cancer Center, Tampa

63110

RECRUITING

Siteman Cancer Center at Washington University, St Louis

77030

NOT_YET_RECRUITING

M D Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope Medical Center, Duarte

94304

NOT_YET_RECRUITING

Stanford Cancer Institute Palo Alto, Palo Alto

98109

NOT_YET_RECRUITING

Fred Hutchinson Cancer Center, Seattle

02115

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER